Gene fusions and fusion products were thought to be unique features of neoplasia. However, more and more studies have identified fusion RNAs in normal physiology. Through RNA sequencing of 27 human noncancer tissues, a large number of fusion RNAs were found. By analyzing fusion transcriptome, we observed close clusterings between samples of same or similar tissues, supporting the feasibility of using fusion RNA profiling to reveal connections between biological samples. To put the concept into use, we selected alveolar rhabdomyosarcoma (ARMS), a myogenic pediatric cancer whose exact cell of origin is not clear. PAX3-FOXO1 (paired box gene 3 fused with forkhead box O1) fusion RNA, which is considered a hallmark of ARMS, was recently found during normal muscle cell differentiation. We performed and analyzed RNA sequencing from various time points during myogenesis and uncovered many chimeric fusion RNAs. Interestingly, we found that the fusion RNA profile of RH30, an ARMS cell line, is most similar to the myogenesis time point when PAX3-FOXO1 is expressed. In contrast, full transcriptome clustering analysis failed to uncover this connection. Strikingly, all of the 18 chimeric RNAs in RH30 cells could be detected at the same myogenic time point(s). In addition, the seven chimeric RNAs that follow the exact transient expression pattern as PAX3-FOXO1 are specific to rhabdomyosarcoma cells. Further testing with clinical samples also confirmed their specificity to rhabdomyosarcoma. These results provide further support for the link between at least some ARMSs and the PAX3-FOXO1-expressing myogenic cells and demonstrate that fusion RNA profiling can be used to investigate the etiology of fusion-gene-associated cancers.
C hromosomal rearrangements that lead to gene fusions are well-known cancer-causing genetic events that are actively used in clinical cancer diagnosis, and their fusion products have been shown to be effective targets of directed therapy (1, 2) . Prominent examples include BCR-ABL in chronic myelogenous leukemia (3) , with the development of imatinib as a paradigm for targeted therapy (4) ; the commonly occurring TMPRSS2-ERG fusion in prostate cancer (5) ; and EML4-ALK and other ALK fusions in lung cancer, which are effectively targeted by crizotinib (6, 7) . The prevailing view is that gene fusions and corresponding fusion products (RNA and protein) are generated due to chromosomal rearrangement at the DNA level and thus are unique to cancer. Even though some gene fusions and fusion transcripts have been reported to be present in nonneoplastic samples (8) (9) (10) , they tend to be expressed at low levels and may be from the precursors of cancer cells. We and others have shown that fusion transcripts can be detected in normal human cell lines (11) and tissues (12) (13) (14) (15) and can be produced by mechanisms other than chromosomal rearrangement.
From our analysis of 210 paired-end RNA sequencing libraries from 171 nonneoplastic tissue samples covering 27 different tissues, a large number of candidate fusion transcripts were uncovered using the SOAPfuse software (15) , contradictory to the conventional wisdom that chimeric RNAs are rare events in noncancer samples. When using the dataset of fusion RNAs to perform clustering analysis, we noticed that samples from the same or similar tissues tended to be grouped together. This observation led us to propose the idea of using fusion transcriptome profiling as a new approach to identify connections between biological samples.
It is well known that specific oncogenic fusions are associated with specific cancer types and thus are useful diagnostic biomarkers. In some situations, the biological basis of this specificity may be rendered by the parental gene expression, as in the case of fusions involving Ig locus. In other situations, the mechanism is not entirely clear. However, recent discoveries on RNA transsplicing in normal cells (16, 17) may shed some light on this enigma. For example, the JAZF1-SUZ12 fusion transcript, which is generated in endometrial stromal sarcomas by a chromosomal translocation event, is produced by RNA trans-splicing in nontransformed, normal endometrial stromal cells (17, 18) . It is possible that oncogenic gene fusions may be selected because they recapitulate processes in cell development or physiology and that normal cells expressing the signature fusion products may be the cells of origin for a particular tumor.
We thus hypothesize that by examining the profile of fusion transcriptome, new insights can be gained about the cell of origin for some cancer. To test the idea, we selected alveolar rhabdomyosarcoma (ARMS) as a model. In studies of ARMS, beyond its association with the skeletal muscle lineage, the exact cell of origin remains heavily debated (19, 20) . Previously, we found that, during normal skeletal muscle differentiation (myogenesis), a PAX3-FOXO1 (paired box gene 3 fused with forkhead box O1) fusion mRNA and protein are expressed in the absence of chromosomal rearrangement (21) . This very fusion protein has Significance Here, we propose an approach to study connections between biological samples. By using binary input of fusion RNA expression, samples of same or similar tissue origin were clustered together. The concept was then put into use to gain insights for the pediatric alveolar rhabdomyosarcoma (ARMS). We found that the signature fusion RNA for ARMS, PAX3-FOXO1 (paired box gene 3 fused with forkhead box O1), and all the other chimeric RNAs expressed in ARMS cells are expressed at the same normal myogenic time point(s). Several chimeric RNAs were further confirmed to be specifically expressed in clinical rhabdomyosarcoma tumor cases. These results support the link between at least some ARMS tumors and the PAX3-FOXO1-expressing myogenic cell. Fusion RNA profiling is a tool to investigate the etiology of fusion-gene-associated cancers.
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Data deposition: The sequences reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE64032). been shown to be critical in the development of the ARMS (22) , in which the predominant driver mutation is a characteristic 2;13 chromosomal translocation resulting in formation of the fusion. We postulate that a unique population of normal muscle progenitor cells is permissive for PAX3-FOXO1 expression. These permissive myogenic cells represent intriguing candidates for the cells of origin for ARMS. This is a similar concept to "conditioned tumorigenicity," in which the tumorigenic effect of a given oncogene is restricted to specific and often quite narrow differentiation or maturation windows within each susceptible lineage (23) . To further support the connection between normal myogenesis and ARMS, we put the concept of fusion transcriptome profiling into use.
Results

Fusion RNA Profiling Connects Samples with Same or Similar Tissue
Origin. From paired-end RNA sequencing libraries covering 27 different tissues of 95 noncancer donors, we detected 16,026 fusion transcripts using a different software, EricScript (24) , which is faster and yielded more fusion transcripts for downstream analysis. Similar to our previous findings, we found that fusion RNA profiles in each tissue or cell type were very different (Fig. S1 ). We then focused on 2,208 recurrent fusions that were detected in more than one sample. The majority of recurrent fusions occurred in only one or two tissue types (578 and 752, respectively). Only a small percent (15%) are found in more than five tissue types (Fig. 1A) .
We performed unsupervised clustering analysis based on fusion RNA expression status (present or absent) in the tissue samples. Most samples from the same tissue type were found to cluster together (Fig. 1B) . For example, all testis and placental samples were in their own clusters, respectively. Samples from tissues with the same embryologic origin were also grouped together (colon, duodenum, stomach, and small intestine). Similarly, traditional transcriptome clustering with fragments per kilobase of transcript per million mapped reads (FPKM) of gene expression also grouped most samples of the same or similar tissue type together, with a few exceptions (Fig. 1C) . For instance, placenta tissues are scattered. These results suggest that the fusion RNA profiling, like traditional transcriptome, can also be used for clustering analysis. In addition, fusion RNA profiling has the advantage of using a binary input (present or absent), whereas the level of expression has to be used for traditional transcriptome profiling.
Numerous Chimeric RNAs Were Transiently Expressed During Myogenesis.
To apply this methodology to a more practical question, we used this fusion transcriptome profiling approach to investigate the cell of origin of the pediatric soft tissue tumor alveolar rhabdomyosarcoma (ARMS). Previously, we detected the PAX3-FOXO1 fusion RNA, which is considered the signature of ARMS, during normal muscle-cell differentiation (21) . To gain more insight into the connection between normal myogenesis and ARMS, we performed RNA-sequencing (RNA-seq) at four time points during the process of mesenchymal stem cell (MSC) muscle differentiation ( Fig. 2A) . A total of 104 chimeric fusion RNAs were identified in samples collected at these four different time points of myogenesis. We identified 33 chimeric fusion RNAs in the ARMS cell line, RH30 ( Fig. 2B and Table S1 ). Of these 137 fusion transcripts, we randomly selected 40 candidates and successfully validated 30 by RT-PCR and traditional Sanger sequencing ( Fig. 2C and Fig. S2 ). We categorized these fusion RNAs into three groups: fusions involving parental genes located on different chromosomes (INTERCHR), fusions involving neighboring genes transcribing the same strand (INTRACHR-SS-0GAP), and other fusions with parental genes on the same chromosome (INTRACHR-OTHER) (Table S1 ). Approximately half of the chimeric RNAs were in the category of INTRACHR-SS-0GAP (72 total), which are candidates for cissplicing between adjacent genes (cis-SAGe). The remaining 65 were potential products of RNA trans-splicing. Of 137 chimeric RNAs, 59 fusions had junction sites in the UTR region, thus not changing protein-coding sequence (NA) ( Table S1 ). In 40 fusions, the protein coding sequence of the 3′ gene used a different reading frame than the 5′ gene (frame-shift). In the remaining 36, the reading frame of the 3′ gene was the same as the 5′ gene (in-frame). Two fusions were labeled "both" because of alternative splicing isoforms that would result in both frame-shift and in-frame. In-frame fusions were significantly enriched (P < 0.05).
Of note, the majority of these chimeric mRNAs were only seen at one time point during the differentiation process and were not seen in undifferentiated cells, indicating their transient nature. The detection of these fusion RNAs at different time points did not correlate with the expression of the 5′ or 3′ parental gene, arguing against the possibility of nonspecific splicing caused by high-level expression of the parental transcripts (Fig. S3 ).
Fusion Transcriptome Analysis Revealed That RH30 and Time Point 3
Have Similar Chimeric RNA Profiles. PAX3-FOXO1 was transiently detected at time point 3 (T3) during myogenic differentiation of the MSCs. Interestingly, four other chimeras-MARS-AVIL, grouped samples from the same tissue type together, as in the case of all placental samples. This analysis used binary format with 1 indicating that the fusion was present (red) and 0 indicating that the fusion was absent (green). We used a variance filter value of 50. Heat maps of the "sample tree" were obtained by "complete lineage clustering" of filtered data. The Pearson correlation matrix was used in this analysis. (C) Similarly, unsupervised clustering with traditional transcriptome expression data was performed.
LINC0045-MEDAG, SEPT7P2-PSPH, and ENO1-EDARADDwere also found by RNA-seq in both the T3 sample and RH30, but not at any other time points (Fig. 2B ). It is unlikely that this co-occurrence is due to random chance (P = 2.7e-06), because T3 has the smallest number of fusions (n = 9), compared to the three other time points (T1, n = 24; T2, n = 49; and T4, n = 22). An unsupervised clustering analysis based on chimeric RNA expression demonstrated the closest similarity between T3 and RH30 (Fig. 3A) , consistent with the hypothesis that T3 has a population of cells that are potential cells of origin for ARMS.
We then used full transcriptome data to perform a similar unsupervised clustering analysis. Overall, the samples from the four differentiation time points were clustered closer to each other than to RH30 (Fig. 3B ). This result is not surprising, because the four time points are all derived from the same MSCs. The lack of connection between T3 and RH30 could be the overall high noise level associated with 24,632 entries (FPKM > 0 in any of the five samples), although a selected group of 1,000 transcripts that had the biggest variation among the five samples also failed to uncover the connection. When we examined closer, we found some common changes in gene expression in both T3 and RH30 when they were compared with T1. To investigate whether the commonality of gene expression between T3 and RH30 is due to the activity of PAX3-FOXO1, a potent transcription activator, we compared the list of up-regulated genes in T3 and RH30 (compared with T1) with the reported PAX3-FOXO1 targets elucidated in a chromatin immunoprecipitation sequencing study (25) . Of the 1,075 up-regulated genes shared by T3 and RH30 cells, ∼9% were targets of PAX3-FOXO1 (98 of a list of 1,072; P < 0.001) (Fig. 3C) , including a few genes encoding myogenic factors that are well-known PAX3-FOXO1 downstream targets, MYOD, EYA2, and EYA4 (25) . Gene Set Enrichment Analysis (26) confirmed the enrichment of PAX3-FOXO1 targets in the commonly up-regulated genes in T3 and RH30 (enrichment score = 0.8, P < 0.001) (Fig. 3D) . These results indicate that transcriptome analyses could also potentially reveal the connection between T3 and RH30 cells, but requires more supervised data mining.
All of the Chimeric RNAs in RH30 Could Be Detected at the Time Point(s) of Myogenesis When PAX3-FOXO1 Was Expressed. In a validation experiment, we repeated the muscle differentiation experiment using a different MSC line, human embryonic stem cell-derived MSCs (hES-MSCs). Considering the high false-negative rate associated with RNA-seq and fusion-mining software, we performed RT-PCR analyses on the samples collected throughout the differentiation process. In this system, PAX3-FOXO1 was transiently expressed at mostly days 2 and 6 and was not detected at later time points (Fig. 4A) . The disappearance at day 4 and reappearance at day 6 is consistent with the wavering expression pattern detected in some of our previous muscle differentiation experiments (21) . Of note, this wavering pattern is not seen with the expression of the parental gene PAX3 or FOXO1 (Fig. S4) , further arguing against the possibility that the fusion is produced due to overwhelming expression of its parental genes. The four other chimeric RNAs previously seen at time point T3 of MSC differentiation and RH30 were also seen at days 2 and 6 of hES-MSC differentiation (Fig. 4A) . We then examined the expression of all other validated fusion RNAs found in RH30 cells by RNA-seq. Remarkably, all of these fusions were detected at the day-2 time point (18/18) and day-6 time point, except for METTL21B-TSFM (17 of 18). Interestingly, seven fusion RNAs, including PAX3-FOXO1, were almost exclusively detected at days 2 and 6 (Fig. 4 A   and 
degree of similarity of RH30 with days 2 and 6, the two time points when PAX3-FOXO1 was detected (Fig. 4C) . Of note, the disappearance of seven fusion RNAs at day 4 and reappearance at day 6 suggests a corresponding wavering pattern of these other fusion RNAs. On one hand, this wavering pattern reflects additional unknown factors involved in the differentiation process; on the other hand, it provides an even stronger argument for the close connection of PAX3-FOXO1-expressing myogenic cells with RH30.
In a separate validation experiment with a commercial mesenchymal stem cell, PAX3-FOXO1 was mostly detected at day 6 and at lower levels detected at day 2 of differentiation ( Fig. S5) . We again performed qRT-PCR analyses on 18 validated fusion RNAs identified by RNA-seq in RH30 cells. Sixteen of these fusions were also found at the day-6 time point (Fig. S5) .
The Chimeras Are Not Downstream Targets of PAX3-FOXO1. The cooccurrence of multiple chimeric RNAs expressed by both RH30 and certain time point(s) during normal myogenesis is highly unlikely to be caused by stochastic chance. Because of the importance of PAX3-FOXO1 in ARMS, we wanted to examine the possibility that the expression of other fusions is triggered by PAX3-FOXO1. We generated MSCs stably expressing PAX3-FOXO1 (MSC/P3F). The level of PAX3-FOXO1 is similar to that in RH30 cells at both RNA and protein levels (Fig. S6) . We then measured expression of these 18 fusion RNAs in MSC/P3F cells. Only one fusion, LINC00545-MEDAG, was apparently induced by PAX3-FOXO1 in this experiment (Fig. 4D) . This finding was also confirmed in 293T cells and a human foreskin fibroblast cell line that were transiently transfected with a PAX3-FOXO1-expressing plasmid. Therefore, we conclude that all of the other fusions detected at the same time point(s) of myogenesis as PAX3-FOXO1 were not simply due to the transcriptional activity of PAX3-FOXO1.
Chimeric RNAs in Sarcoma Cell Lines and Clinical Samples. We then examined the fusion RNAs in other rhabdomyosarcoma (RMS) cell lines, including PAX3-FOXO1-positive and -negative lines. Most of the fusion RNAs could be detected in at least one additional RMS cell line (RH30 and RMS-13 were derived from the same patient; ref. 27) (Fig. 5A) . We also tested these fusions in eight cell lines belonging to six other sarcoma cell types: 402-91 (myxoid liposarcoma), JN-DSRCT (desmoplastic small round cell sarcoma), SUCCS-1 (clear cell sarcoma), OsACL (osteosarcoma), A2243 (synovial sarcoma), and A673, TTC-466, and TC32 (Ewing sarcoma). Nine of the 18 fusions were only seen in RMS cells. Interestingly, the seven fusions that matched PAX3-FOXO1 expression pattern in Fig. 4A were very specific to RMS cells (WARS2-TBX15 had weak signal in other sarcoma lines) (Fig. 5 A and B) .
To rule out the possibility of cell culture artifact, we measured the fusions in a panel of clinical RMS tumor cases consisting of five PAX3-FOXO1 (P3F)-positive cases, three PAX7-FOXO1 (P7F)-positive cases and six fusion-negative RMS cases (Fig. S7) . As controls, we included fetal and adolescent muscle biopsies, as well as RH30 cells. To test for RMS specificity, we also included clinical samples of other "small round blue cell" tumors. Consistent with the cell line data (Fig. 5 A and B) , several fusion RNAs, including MEGF11-TIPIN, SYNE3-LINC00341, and THSD4-SERHL2 were found to be specific to RMS. They were detected in P3F, P7F, and PF-negative RMS cases, but not in synovial sarcoma, liposarcoma, desmoplastic small round cell sarcoma, osteosarcoma, or Ewing sarcoma samples (Fig. 5C) .
The presence of the same set of fusion RNAs in both normal myogenesis and RMS could be attributed to the possibility that they contribute directly to tumorigenesis (i.e., beneficial to the tumor cells, as in the case of PAX3-FOXO1). It is also possible that they are simply bystanders and are not detrimental to the tumor cells. Not surprisingly, many fusions were also found in the fetal muscle sample, but most were undetected or only weakly expressed in the adolescent muscle sample. This finding is consistent with the transient nature of these fusion RNAs observed in the MSC differentiation system. Several chimeric RNAs, including MEGF11-TIPIN, SYNE3-LINC00341, THSD4-SERHL2, and ROBO1-XPC, displayed higher expression in RH30, as well as in certain individual RMS cases, compared with the fetal muscle sample. This differential expression could be because of the greater degree of homogeneity, in terms of cell types expressing the fusions, in the tumor samples compared with the fetal sample. Conversely, it is also possible that the fusions are beneficial to tumorigenesis, leading to their selective preservation. We are carrying out functional studies on several of such fusions. In contrast, several chimeric RNA, including LINC00545-MEDAG, had similar levels of expression in the fetal samples and the clinical samples (Fig. S8) , suggesting that they are most likely bystanders.
Discussion
ARMS is an aggressive soft-tissue cancer that most commonly occurs in children and adolescents. This cancer often occurs in limbs and expresses markers of immature muscle (MYOD and MYOG). Even with collaborative national trials of multimodal therapy, the outcome for patients with advanced-stage ARMS has not improved over the last few decades. The cell of origin for this tumor is currently not clear. The lack of an answer to this basic question has impeded the understanding of the tumor etiology. This issue may also be clinically relevant, because a recent study demonstrated that the lineage of origin significantly influences sensitivity to target therapeutics (20) .
Over the years, various experimental systems have been used to address the cell-of-origin question, but they have yielded confusing and conflicting results (19, 20) . Some evidence suggests that MSCs may be the cell of origin for ARMS (19) ; some evidence supports myogenic satellite cells (28) ; and others propose terminally differentiated muscle cells or fetal myoblasts (20, 29) . The disagreement partially stems from the traditional "candidate cell" approach: In both cell culture and animal model systems, certain types of cells were selected and tested to determine whether they could be transformed upon the introduction of "oncogenic" factors, such as PAX3-FOXO1. However, cells that are accessible and can be transformed are not necessarily the cells from which a particular tumor arises. The best support for this argument is that throughout the history of cancer research, the mouse fibroblast cell line NIH 3T3 has been widely used to test different oncogenic factors found in different tumor types. We now propose a different strategy by monitoring the cancer-signature chimeric RNAs associated with the tumor throughout the normal muscle cell differentiation process. We propose that the pattern of fusion RNA expression can be used as a fingerprint to identify candidates for cell of origin. Here, chimeric RNA profiling is used to provide hints for the etiology of a disease.
The fact that PAX3-FOXO1 is expressed both in certain cells during normal myogenesis and in ARMS supports the connection between the two. However, an alternative hypothesis is that inappropriate PAX3-FOXO1 expression in a lineage that does not normally express this fusion may be oncogenic. We found that an additional 17 chimeric RNAs were shared between the two cells and that seven fusions had identical transient expression pattern as PAX3-FOXO1, strongly arguing against this ectopic expression theory, because it is highly unlikely that an unrelated cell population would acquire all these fusions associated with normal myogenesis. Another important issue is the finding that, when expressed ectopically in many cell types, the PAX3-FOXO1 protein, as well as other oncogenic fusion products, triggers growth arrest and/or cell death (30, 31) . The fact that endogenous PAX3-FOXO1 and other fusion RNAs are found in some normal myogenic cells supports the possibility that ARMS may originate from these cells, because they are permissive for, if not responsive to, these fusions.
The fusion transcriptome clustering with a binary input (presence or absence of a chimera) performed as well as traditional transcriptome clustering in human body maps (Fig. 1) . It uncovered a connection between normal myogenesis and ARMS (Fig. 3A) that could not be revealed directly by using wholetranscriptome analyses (Fig. 3B) . However, the connection between the fusion transcript and gene fusion at the chromosomal level is not clear. In addition, more studies are needed to understand the regulation mechanism of the fusion transcripts, including their transient nature, and their specificity.
Materials and Methods
Cell Lines and Culture Conditions. MSCs were obtained from the Tulane University Center for Gene Therapy. hES-MSCs were obtained from Millipore.
RNA-Seq and Bioinformatics Analyses. MSC muscle differentiation and RH30 cell RNA-seq were performed by Axeq. The deep-sequencing data were mapped to human genome version hg19 and analyzed by using the software SOAPfuse (32) . The human tissue RNA-seq was analyzed by EricScript (24) . The identified chimeric RNAs were presented by using Circos as described (33) . For the heat-map generation and clustering, MultiExperimentViewer software was used.
RT-PCR and Sanger Sequencing. Fusion candidates were validated at the RNA level by standard RT-PCR or qRT-PCR with primers listed in Table S2 . After RT-PCR and gel electrophoresis, all purified bands were sent for Sanger sequencing.
Ethics Approval and Consent to Participate. All RMS tumor samples were deidentified. Expression studies of these tumor samples was designated as exempt by the National Institutes of Health Office of Human Subjects Research.
the raw data, the software FastQC was used. The deep-sequencing data were mapped to Human genome version hg19 and analyzed by using the software SOAPfuse (32) . The identified chimeric RNAs were presented by using Circos as described (33) . On the same Circos plots, gene expression was also plotted.
The 210 paired-end RNA sequencing libraries from 171 nonneoplastic tissue samples, including 27 different tissues (36) and cell lines (37) (38) (39) (40) , have been described (15) . Previously, we used SOAPfuse for fusion RNA identification. Here, we used another software tool, EricScript (24), for fusion RNA discovery. The default setting was used to nominate a fusion transcript.
For the heat-map generation and clustering, MultiExperimentViewer (MeV) software was used. MeV is a component of the TM4 suite, which is an open-source Java application, and is hosted at SourceForge (41). The method used was hierarchical clustering with complete linkage as the agglomeration rule. The Pearson correlation coefficient was used to measure the similarity between gene profiles, and Spearman rank was used to measure the similarity between samples. Gene Set Enrichment Analysis (26) was performed to reveal the enrichment of PAX3-FOXO1 targets in commonly up-regulated genes in T3 and RH30.
RT-PCR and Sanger Sequencing. Fusion candidates were validated at the RNA level by standard RT-PCR or qRT-PCR. qRT-PCR was performed by using the ABI Step One Plus Real-Time PCR system (Life Technologies) following the manufacturer's instructions. We designed specific primer pairs (Table S2 ) with each primer targeting one parental gene. After RT-PCR and gel electrophoresis, all purified bands were sent for Sanger sequencing. S4 . PAX3 -FOXO1, PAX3, and FOXO1 expression throughout muscle differentiation. Experiments were conducted as described in Fig. 4 . Expression levels of these transcripts were normalized to GAPDH and then normalized to that in RH30. Expression levels of these chimeric transcripts were normalized to GAPDH and then normalized to that in RH30. ROBO1-XPC displayed higher expression in RH30, as well as in some RMS cases; expression was nearly absent in the fetal or adolescent muscle sample. In contrast, LINC00545-MEDAG had similar levels of expression in the fetal muscle sample and the clinical samples. Table S1 . Cont.
Characterization of the fusions based on chromosomal location and protein coding potential were listed. Highlighted rows indicate the ones that were selected for validation. N, no; NA, not applicable; Y, yes.
